• D E Vlachos, N Thomakos, D Haidopoulos, V Pergialiotis, V Theodoulidis, A Protopapas, and A Rodolakis.
• Gynecologic Oncology Unit, 1st Department of Obstetricsa and Gynecology, National and Kapodistrian University of Athens, Athens, Greece.
• Niger J Clin Pract. 2022 Jun 1; 25 (6): 739-746.

AbstractThe genital system remains one of the most common sites of carcinogenesis in women. Advances in surgery, radiation treatment, and chemotherapy have increased their efficacy and many patients survive for many years after their initial diagnosis. The eye is a rare site of metastasis from gynecological cancer due to its distant location from the genitalia. In this systematic review, we retrieved all case reports of patients with ocular metastasis from gynecological neoplasms. The demographic, clinical, and treatment characteristics were retrieved and analyzed. A total of 70 case reports were included. Forty-eight of these reports concerned patients with a known malignancy that recurred in the eye and in 22 patients' ocular symptomatology accompanied the initial diagnosis of the gynecologic malignancy. 73.9% of these patients exhibited concomitant metastasis to other organs. The mean disease-free interval was found at 25.7 months and mean survival time after the eye metastasis was 13.5 months. Refractory disease was identified as the most important risk factor associated with mortality. Because eye metastasis has such a dismal prognosis, all gynecologists who treat oncological patients should be highly suspicious for reported eye complaints.

16 keywords...

hide…